Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 1998, for Aastrom Biosciences, Inc. (Note: The input metadata referenced "Vericel Corp," but the filing text explicitly identifies the registrant as Aastrom Biosciences, Inc.). The Company is in the development stage, focusing on research and product development for the ex vivo production of human stem cells and hematopoietic tissues. It has not yet generated revenue from product sales and does not expect to achieve profitability for several years.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 1998 | Nine Months Ended Mar 31, 1998 | Balance Sheet (Mar 31, 1998) |
|---|---|---|---|
| Total Revenues | $80,000 | $145,000 | - |
| Net Loss | $(5,355,000) | $(13,388,000) | - |
| Net Loss Per Share (Basic/Diluted) | $(0.41) | $(1.28) | - |
| Cash and Cash Equivalents | - | - | $2,671,000 |
| Short-term Investments | - | - | $12,763,000 |
| Total Current Assets | - | - | $15,845,000 |
| Total Current Liabilities | - | - | $3,032,000 |
| Accumulated Deficit | - | - | $(54,900,000) |
| Net Cash Used in Operating Activities | - | $(11,486,000) | - |
Material Changes vs. Prior Period
- Revenue: Quarterly revenue increased to $80,000 from $68,000 in the prior year quarter, driven by grant funding. However, nine-month revenue decreased to $145,000 from $321,000, reflecting the completion of a research collaboration in September 1996.
- Expenses: Total costs and expenses rose to $5,688,000 for the quarter (from $4,718,000) and $14,215,000 for the nine months (from $11,319,000). This increase is primarily due to higher Research and Development (R&D) expenses ($4,966,000 for the quarter) related to the Aastrom Cell Production System (CPS).
- Net Loss: The net loss widened to $5,355,000 for the quarter and $13,388,000 for the nine months compared to the prior year periods.
- Liquidity: Combined cash, cash equivalents, and short-term investments totaled $15,434,000 at March 31, 1998, a decrease of $1,573,000 from June 30, 1997, despite a December 1997 preferred stock offering that raised approximately $9,930,000.
Guidance, Outlook, and Risks
- Outlook: The Company does not expect positive cash flow from operations until product sales commence. Operating expenses are expected to continue to increase as R&D programs progress. The Company anticipates needing additional funding through collaborative arrangements or public/private financing.
- Capital Resources: In December 1997, the Company sold 2,200,000 shares of 5.5% Convertible Preferred Stock. In March 1998, it issued common stock valued at approximately $152,000 to pay quarterly dividends on this preferred stock.
- Key Risks:
- Regulatory Approval: FDA approval is required for commercial sales; there is no assurance of success.
- Clinical Trials: Pre-pivotal trials are ongoing. Patient mortality or severe complications in trials could delay or halt development.
- Supply Chain: Reliance on third-party manufacturers for key components (cytokines, serum) creates supply risk.
- Commercialization: Success depends on market acceptance of the Aastrom CPS and the performance of its distribution partner, Cobe BCT, Inc.
- Unusual Items: The computation of net loss per share for the nine months ended March 31, 1998, included a one-time charge of $3,439,000 related to the sale of Preferred Stock. This charge affects per-share calculations but is not included in the net loss figure.
Investor Verification Checklist
- Verify the status and results of the pre-pivotal clinical trials for the Aastrom Cell Production System (CPS).
- Confirm the terms and stability of the distribution agreement with Cobe BCT, Inc., including the termination clause effective December 31, 1998.
- Assess the Company's ability to secure additional funding given the accumulated deficit of $54.9 million and continued operating losses.
- Review the timeline for FDA regulatory approval and the potential impact of delays on cash burn rates.
- Monitor the availability and cost of third-party manufactured components (cytokines, animal-derived products) required for production.